Loading stock data…
$3.16-0.09 (-2.77%)
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. in the Healthcare sector is trading at $3.16 with a market capitalization of $133M. Wall Street consensus targets $20.00 (6 analysts), implying a +532.9% move over the next 12 months. The stock is currently near its 52-week low of $3.06, remaining 62.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.49M↑ | $1.90M↑ | $1.59M↓ | $12.50M↑ | $5.00M |
| Gross Profit | $5.21M↑ | $825,000 | — | — | $5.00M |
| Operating Income | -$34.17M↑ | -$44.13M↓ | -$38.46M↓ | -$18.89M↓ | -$16.86M |
| Net Income | -$31.92M↑ | -$41.49M↓ | -$35.90M↓ | -$16.70M↓ | -$14.91M |
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of pre...